WisdomTree, Inc. (WT) closed the last trading session at $11.8, gaining 7.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.13 indicates a 28.2% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $1.5. While the lowest estimate of $13.25 indicates a 12.3% increase from the current price level, the most optimistic analyst expe ...

Shares of Photronics (PLAB) have gained 60.2% over the past four weeks to close the last trading session at $32.96, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $43.23 indicates a potential upside of 31.2%.The average comprises three short-term price targets ranging from a low of $42.00 to a high of $45.00, with a standard deviation of $1.57. While the lowest estimate indicat ...

Shares of Figure Technology (FIGR) have gained 0.2% over the past four weeks to close the last trading session at $37.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.11 indicates a potential upside of 31.7%.The mean estimate comprises nine short-term price targets with a standard deviation of $6.17. While the lowest estimate of $40.00 indicates a 7.3% increase from the c ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about M/I Homes (MHO) .M/I Homes currently has an average brokerage recommendati ...

Slide Insurance Holdings, Inc. (SLDE) closed the last trading session at $18.21, gaining 11.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.8 indicates a 25.2% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $2.05. While the lowest estimate of $21.00 indicates a 15.3% increase from the current price level, the most opti ...

Shares of VAREX IMAGING (VREX) have gained 3.2% over the past four weeks to close the last trading session at $11.8, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 29.9%.The mean estimate comprises three short-term price targets with a standard deviation of $3.06. While the lowest estimate of $12.00 indicates a 1.7% increase from the curre ...

Shares of Galp Energia SGPS SA (GLPEY) have been struggling lately and have lost 16.4% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish c ...

Core Viewpoint - Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Barinthus Biotherapeutics signifies an improvement in the company's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the tracking of earnings estimate revisions a valuable investment strategy [5][7]. - Barinthus Biotherapeutics has seen a 1.1% increase in the Zacks Consensus Estimate over the past three months, indicating a positive trend in earnings expectations [9]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The upgrade to Zacks Rank 2 places Barinthus Biotherapeutics in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10][11].

Daktronics (DAKT) closed the last trading session at $18.77, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.67 indicates a 26.1% upside potential.The average comprises three short-term price targets ranging from a low of $16.00 to a high of $31.00, with a standard deviation of $7.51. While the lowest estimate indicates a decline of 14.8% from the current price lev ...

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has shown a 13% gain over the past four weeks, with a mean price target of $12.62 indicating a potential upside of 134.1% from the current price of $5.39 [1] Price Targets and Analyst Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $6.67, where the lowest estimate is $8.00 (48.4% increase) and the highest is $30.00 (456.6% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CMPX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, indicating a positive outlook [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]